By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Diffusion Pharmaceuticals 

2020 Avon Court, Suite 4

Charlottesville  Virginia  22902  U.S.A.
Phone: 434-220-0718 Fax: 434-220-0722



Drug Discovery

Company News
Diffusion Pharma Establishes Scientific Advisory Board 9/29/2016 11:05:29 AM
Diffusion Pharma Successfully Completes Animal Toxicity Studies In Preparation For Phase III Pivotal Trial Of TSC In New Diagnosed Glioblastoma Patients 9/19/2016 8:36:35 AM
Diffusion Pharma To Present At 18th Annual Rodman & Renshaw Global Investment Conference 9/9/2016 7:30:35 AM
Diffusion Pharma Announces Reverse Stock Split In Preparation For Proposed Uplisting To NASDAQ Capital Market 8/18/2016 7:58:46 AM
Diffusion Pharma Announces Acceptance Of Abstract On Use Of TSC In Hypoxia Driven Medical Emergencies At ACEP 2016 Research Forum 7/6/2016 7:50:52 AM
RestorGenex (RESX) and Diffusion Pharma Merge to Form Wholly-Owned Oncology Subsidiary 12/28/2015 7:20:50 AM
Diffusion Pharmaceuticals To Present At Cavendish Global Health Impact Forum 10/30/2014 10:06:01 AM
Diffusion Pharmaceuticals Clinical Trial Of TSC In Brain Cancer Reaches One Year Interim Endpoint 5/15/2014 9:53:20 AM
Diffusion Pharmaceuticals Closes $5 Million Financing; Completes Enrollment and Dosing in Phase 2 Trial In Brain Cancer 6/20/2013 9:06:59 AM
Diffusion Pharmaceuticals Receives FDA Orphan Designation for TSC, a First-in-Class Drug for the Treatment of Metastatic Brain Cancer 12/11/2012 10:16:26 AM